Scientists at Cedars‑Sinai Health Sciences University have pinpointed an enzyme, UBE2N, that appears to shield the liver from the damage that drives metabolic dysfunction‑associated steatohepatitis (MASH), the severe form of fatty liver disease. The discovery, reported in a pre‑clinical study published in Nature Metabolism, could lay the groundwork for therapies aimed at halting disease progression before liver failure sets in.
Scope of the problem
According to the American Liver Foundation, roughly 100 million Americans live with metabolic dysfunction‑associated steatotic liver disease (MASLD), the condition previously known as non‑alcoholic fatty liver disease. Of those, an estimated 20 % to 25 % advance to MASH, a stage marked by excess liver fat combined with inflammation, cellular injury and fibrosis. Current management relies largely on lifestyle modification, with limited pharmacologic options and no cure for MASH.
Key findings from the study
The Cedars‑Sinai team observed that levels of UBE2N decline in liver cells as MASLD progresses toward MASH. “The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat,” explained Dr. Ekihiro Seki, MD, PhD, professor of Medicine and Biomedical Sciences and co‑corresponding author of the study. In laboratory mice engineered to restore normal UBE2N levels, researchers recorded a notable reduction in hepatic fat accumulation, inflammatory markers and scar tissue formation.
These outcomes suggest that UBE2N functions as a natural defense mechanism, promoting the clearance of malfunctioning mitochondria—a process known as mitophagy—and facilitating lipid metabolism. When the enzyme’s activity wanes, damaged mitochondria accumulate, triggering pathways that lead to cell death and fibrosis.
Implications for future treatment
Dr. Shelly Lu, MD, Women’s Guild Chair in Gastroenterology and director of the Karsh Division of Gastroenterology and Hepatology at Cedars‑Sinai, highlighted the significance of the findings: “The identification of this enzyme’s role in regulating mitochondria in the liver is an important advance in understanding steatotic liver disease. Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease.”
While the research is still in the pre‑clinical stage, the authors propose that pharmacologic activation of UBE2N or gene‑therapy strategies to restore its activity could become part of a multi‑modal approach to managing MASLD. Such interventions might be combined with lifestyle counseling and existing medications to provide a more comprehensive defense against liver injury.
The study was a collaborative effort involving researchers from multiple institutions, including co‑authors Michitaka Matsuda, So Yeon Kim, Takashi Tsuchiya and Yoon Seok Roh, among others. Funding was supplied by a range of agencies, notably the National Research Foundation of Korea, the American Association for the Study of Liver Diseases, the National Institutes of Health and the National Natural Science Foundation of China.
As the prevalence of fatty liver disease continues to rise, the identification of UBE2N adds a promising piece to the puzzle of how the liver protects itself from metabolic stress. Ongoing investigations will determine whether the enzyme can be safely targeted in humans and whether such interventions can translate into measurable reductions in MASH incidence and progression.
Helene Elliott is the Lead Science & Space Reporter at News Raise. She reports on aerospace missions, astrophysics discoveries, quantum research, and environmental technology.
